Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Pantumor MRD-undersøgelse

22. september 2026 opdateret af: Paradigm Health

Molecular Residual Disease in Solid Tumors: En prospektiv undersøgelse til indsamling af kliniske data og bioprøver til støtte for opdagelse og udvikling af cancerbiomarkører

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back.

Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.

Studieoversigt

Undersøgelsestype

Observationel

Tilmelding (Anslået)

1350

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35205
    • Arizona
      • Bullhead City, Arizona, Forenede Stater, 86442
        • Rekruttering
        • Mohtaseb Cancer Center and Blood Disorders
        • Ledende efterforsker:
          • Hamdy Mohtaseb
        • Kontakt:
      • Casa Grande, Arizona, Forenede Stater, 85122
        • Rekruttering
        • Cancer & Blood Specialists of Arizona
        • Kontakt:
        • Ledende efterforsker:
          • Carlos Arce-Lara
    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 72205
        • Rekruttering
        • CARTI
        • Kontakt:
        • Ledende efterforsker:
          • Andrew Briggler
      • Springdale, Arkansas, Forenede Stater, 72762
        • Rekruttering
        • Highlands Oncology Group (HOG)
        • Ledende efterforsker:
          • Joseph Beck
        • Kontakt:
    • California
      • Glendale, California, Forenede Stater, 91204
        • Rekruttering
        • Los Angeles Cancer Network (LACN)
        • Kontakt:
        • Ledende efterforsker:
          • Peyman Salimi-Tari
      • Oxnard, California, Forenede Stater, 93030
        • Rekruttering
        • Ventura County Hematology Oncology Specialists
        • Kontakt:
        • Ledende efterforsker:
          • Lynn Kong
      • San Diego, California, Forenede Stater, 92123
      • San Diego, California, Forenede Stater, 92123
        • Rekruttering
        • Medical Oncology Associates of San Diego (MOASD)
        • Kontakt:
        • Ledende efterforsker:
          • James Coggan
      • Stockton, California, Forenede Stater, 95204
        • Rekruttering
        • Stockton Hematology Oncology Med Group
        • Kontakt:
        • Ledende efterforsker:
          • Sunny Phillip
    • Colorado
      • Englewood, Colorado, Forenede Stater, 80113
    • Florida
      • Coral Springs, Florida, Forenede Stater, 33065
        • Rekruttering
        • Oncology & Hematology Associates of West Broward
        • Ledende efterforsker:
          • Sumit Sawhney
        • Kontakt:
      • Orange City, Florida, Forenede Stater, 32763
        • Rekruttering
        • Mid Florida Cancer Centers
        • Ledende efterforsker:
          • Santosh Nair
        • Kontakt:
      • St. Petersburg, Florida, Forenede Stater, 33709
        • Rekruttering
        • Comprehensive Hematology Oncology (CHO)
        • Ledende efterforsker:
          • Neeharika Makani
        • Kontakt:
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30318
        • Rekruttering
        • Piedmont Cancer Institute
        • Kontakt:
        • Ledende efterforsker:
          • Vasileios Assikis
    • Illinois
      • O'Fallon, Illinois, Forenede Stater, 62269
        • Rekruttering
        • Cancer Care Specialists of Illinois (CCSI)
        • Ledende efterforsker:
          • James Wade
        • Kontakt:
      • Urbana, Illinois, Forenede Stater, 61801
        • Rekruttering
        • Carle Health
        • Kontakt:
        • Ledende efterforsker:
          • Christine Canfield
    • Kansas
      • Topeka, Kansas, Forenede Stater, 66606
        • Rekruttering
        • Cotton O'Neil Cancer Center [Stormont Vail]
        • Kontakt:
        • Ledende efterforsker:
          • Mehmmod Hashmi
      • Wichita, Kansas, Forenede Stater, 67214
    • Kentucky
      • Corbin, Kentucky, Forenede Stater, 40701
        • Rekruttering
        • Baptist Health Corbin
        • Kontakt:
        • Ledende efterforsker:
          • Abigail Byrnes
      • Elizabethtown, Kentucky, Forenede Stater, 42701
        • Rekruttering
        • Baptist Health Hardin
        • Kontakt:
        • Ledende efterforsker:
          • Christopher Burkeen
      • Lexington, Kentucky, Forenede Stater, 40503
        • Rekruttering
        • Baptist Health Lexington
        • Ledende efterforsker:
          • Arvinda Padmanabhan
        • Kontakt:
      • Louisville, Kentucky, Forenede Stater, 40207
        • Rekruttering
        • Baptist Health Louisville
        • Ledende efterforsker:
          • Wangjian Zhong
        • Kontakt:
    • Louisiana
      • Covington, Louisiana, Forenede Stater, 70433
        • Rekruttering
        • Pontchartrain Cancer Center
        • Ledende efterforsker:
          • David Oubre
        • Kontakt:
      • Shreveport, Louisiana, Forenede Stater, 71105
        • Rekruttering
        • Christus Health Highlands
        • Kontakt:
        • Ledende efterforsker:
          • Neelima Chintapalli
    • Michigan
      • Grand Rapids, Michigan, Forenede Stater, 49546
        • Rekruttering
        • The Cancer & Hematology Centers (CHC)
        • Kontakt:
        • Ledende efterforsker:
          • Joy Bartholomew
    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Rekruttering
        • Mayo Clinic
        • Kontakt:
        • Ledende efterforsker:
          • Lisa Boardman
    • Missouri
      • Springfield, Missouri, Forenede Stater, 65807
        • Rekruttering
        • Cox Health
        • Kontakt:
        • Ledende efterforsker:
          • Rajesh Banderudrappagari
    • Nebraska
      • Lincoln, Nebraska, Forenede Stater, 68516
        • Rekruttering
        • Cancer Partners of Nebraska
        • Kontakt:
        • Ledende efterforsker:
          • Stacey Knox
    • New Mexico
      • Farmington, New Mexico, Forenede Stater, 87401
        • Rekruttering
        • San Juan Oncology Associates
        • Ledende efterforsker:
          • Sardar Imam
        • Kontakt:
    • New York
      • Binghamton, New York, Forenede Stater, 13905
        • Rekruttering
        • Guthrie Lourdes Memorial Hospital (GLMH)
        • Ledende efterforsker:
          • Beka Aroshidze
        • Kontakt:
      • Shirley, New York, Forenede Stater, 11967
        • Rekruttering
        • New York Cancer & Blood Specialists
        • Ledende efterforsker:
          • Richard Zuniga
        • Kontakt:
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28207
        • Rekruttering
        • Carolina Oncology Specialists
        • Ledende efterforsker:
          • Justin Favaro
        • Kontakt:
      • Goldsboro, North Carolina, Forenede Stater, 27534
        • Rekruttering
        • Southeastern Medical Oncology Center (SMOC)
        • Kontakt:
        • Ledende efterforsker:
          • Samer Kasbari
      • Wilson, North Carolina, Forenede Stater, 27893
        • Rekruttering
        • Regional Medical Oncology Center
        • Ledende efterforsker:
          • Keith Lerro
        • Kontakt:
    • Ohio
      • Canton, Ohio, Forenede Stater, 44718
        • Rekruttering
        • Gabrail Cancer Center
        • Ledende efterforsker:
          • Nashat Gabrail
        • Kontakt:
      • Maumee, Ohio, Forenede Stater, 43437
        • Rekruttering
        • Taylor Cancer Research Center
        • Kontakt:
    • Oklahoma
      • Tulsa, Oklahoma, Forenede Stater, 74129
        • Rekruttering
        • Oklahoma Cancer Specialists and Research Institute (OCSRI)
        • Kontakt:
        • Ledende efterforsker:
          • Scott Cole
    • Oregon
      • Portland, Oregon, Forenede Stater, 97201
        • Rekruttering
        • Oregon Health & Science University (OHSU)
        • Ledende efterforsker:
          • Nima Nabavizadeh
        • Kontakt:
    • Pennsylvania
      • Lancaster, Pennsylvania, Forenede Stater, 17601
      • Sayre, Pennsylvania, Forenede Stater, 18840
        • Rekruttering
        • Guthrie Foundation
        • Kontakt:
        • Ledende efterforsker:
          • Rebekah Macfie
      • York, Pennsylvania, Forenede Stater, 17403
        • Rekruttering
        • Cancer Care Associates of York (CCAY)
        • Ledende efterforsker:
          • Chanh Huynh
        • Kontakt:
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • Onocology Consultants P.A. (Oncology Consultants [OC Houston])
        • Ledende efterforsker:
          • Julio Peguero
        • Kontakt:
      • Kingwood, Texas, Forenede Stater, 77339
        • Rekruttering
        • Community Clinical Trials
        • Ledende efterforsker:
          • Saleha Sajid
        • Kontakt:
      • Texarkana, Texas, Forenede Stater, 75503
    • Virginia
      • Richmond, Virginia, Forenede Stater, 23229
        • Rekruttering
        • Virginia Cancer Institute
        • Kontakt:
        • Ledende efterforsker:
          • Susan Moore
    • Washington
      • Tacoma, Washington, Forenede Stater, 98405
        • Rekruttering
        • Northwest Medical Specialties (NWMS)
        • Kontakt:
        • Ledende efterforsker:
          • Manas Agastya

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Study participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors

Beskrivelse

Eligibility Criteria:

  1. Age 18 years or older.

  2. Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1).

  3. Eligible for curative intent therapy, with surgical resection of cancer planned.

    a. If surgical resection has occurred, enrollment should occur within 3 months of surgical resection and before initiation of adjuvant therapy.

  4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2.

  5. No systemic therapy for current cancer diagnosis administered before enrollment.

  6. Willing and able to comply with required study procedures, including blood sample collection and primary tumor tissue submission from diagnostic biopsy or surgical excision.

  7. Has completed all therapy (including endocrine therapy) 3 or more years ago for any previous invasive solid organ malignancy (with exception of nonmelanoma skin cancers) or hematologic malignancy. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment (no washout period required).

  8. No concurrent diagnosis of another invasive cancer, except for nonmelanoma skin cancers.

  9. No prior allogeneic hematopoietic stem cell transplant.

  10. Able and willing to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for the release of personal health information.

    Cohort Specific Criteria

  11. Muscle-invasive urothelial carcinoma of the bladder and Melanoma Cohorts: Stage II or operable III cancer:

  12. Esophageal, Gastric/GEJ, and NSCLC Cohorts: Stage I, II, or operable III cancer.

  13. Pancreatic Cohort: Stage I, II or operable III cancer, exocrine only disease.

  14. MOST cohort: Stage II or operable stage III solid tumor diagnosis that meets eligibility criteria and is not included in the other cohorts.

The following tumor types are excluded:

  1. Central nervous system (CNS) malignancies

  2. Colorectal cancer

  3. Breast cancer

  4. Squamous cell skin cancer

  5. Basal cell carcinoma

  6. Gastrointestinal stromal tumors (GIST)

  7. Thyroid cancer

  8. Uveal melanoma

  9. Low or intermediate grade neuroendocrine tumors

    ■ Eligible tumor types: High-grade neuroendocrine tumors, including neuroendocrine carcinomas, Merkel cell carcinomas, and small cell lung cancer are permissible

  10. Hematologic cancers including multiple myeloma or other plasma cell dyscrasias, Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute or chronic leukemias including chronic lymphocytic leukemia / small lymphocytic leukemia

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

routine standard of care

Routine standard of care

Esophageal

Esophageal cancer

routine standard of care

Routine standard of care

Gastric and Gastroesophageal Junction (GEJ)

Gastric and Gastroesophageal Junction (GEJ)

routine standard of care

Routine standard of care

Melanoma

Melanoma

routine standard of care

Routine standard of care

Non-small cell lung (NSCLC)

Non-small cell lung (NSCLC)

routine standard of care

Routine standard of care

Pancreatic (exocrine only)

Pancreatic (exocrine only)

routine standard of care

Routine standard of care

Mix of Solid Tumors (MOST)

Mix of Solid Tumors (MOST)

routine standard of care

Routine standard of care

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Blood and tissue biospecimen registry
Tidsramme: Observation from enrollment to 5.5 years after enrollment

To establish a blood and tissue biospecimen resource in participants with operable solid tumors, with clinical, lab, radiographic, and pathology annotation for the discovery, development, and validation of MRD assays.

Observation from enrollment to 5.5 years after enrollment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. januar 2025

Primær færdiggørelse (Anslået)

1. december 2031

Studieafslutning (Anslået)

1. april 2032

Datoer for studieregistrering

Først indsendt

18. september 2024

Først indsendt, der opfyldte QC-kriterier

18. september 2024

Først opslået (Faktiske)

20. september 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

24. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. september 2026

Sidst verificeret

1. september 2026

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner